Arax Advisory Partners’s Zevra Therapeutics ZVRA Stock Holding History

Arax Advisory Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.6K	Buy	+806	New	+$8.96K	﹤0.01%	4261
2026 Q1	–	Sell	-87	Closed	-$780	–	4394
2025 Q4	$780	Buy	+87	New	+$823	﹤0.01%	3535
2025 Q1	–	Sell	-87	Closed	-$726	–	3088
2024 Q4	$726	Hold	87	–	–	﹤0.01%	2243
2024 Q3	$604	Hold	87	–	–	﹤0.01%	2375
2024 Q2	$427	Buy	+87	New	+$412	﹤0.01%	2350

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arax Advisory Partners's ZVRA Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 806 shares worth $11.6K. The stake represents ﹤0.01% of the portfolio and ranks #4261 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in ZVRA as recently as Q4 2025.

Arax Advisory Partners first reported a position in ZVRA in Q2 2024 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Arax Advisory Partners held 806 shares of Zevra Therapeutics worth $11.6K as of Q2 2026.
Zevra Therapeutics was a new Arax Advisory Partners position in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4261 holding.
Arax Advisory Partners first reported a position in Zevra Therapeutics in Q2 2024 and has held it in 5 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.